Stockscreener 앱 받기
4.25
0.23%
-0.010
시간 외 거래:
4.27
0.02
+0.47%
전일 마감가:
$4.26
열려 있는:
$4.27
하루 거래량:
2.81M
Relative Volume:
0.90
시가총액:
$720.10M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-212.50
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
-3.19%
1개월 성능:
+11.55%
6개월 성능:
+71.37%
1년 성능:
+300.94%
1일 변동 폭
$4.21
$4.66
1주일 범위
$4.07
$4.66
52주 변동 폭
$0.40
$4.66
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.25 | 721.79M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX Therapeutics (NASDAQ:CTMX) Hits New 1-Year HighHere's Why - MarketBeat
What drives CytomX Therapeutics Inc stock priceWeekly Market Snapshot & Investor Community Interactions - earlytimes.in
Chart Watch: Is CytomX Therapeutics Inc stock a safe investment in uncertain markets2025 Bull vs Bear & Verified Short-Term Trading Plans - moha.gov.vn
Will CytomX Therapeutics Inc. stock recover faster than peersChart Pattern Recognition & Exceptional Return Stocks - bollywoodhelpline.com
237,081 Shares in CytomX Therapeutics, Inc. $CTMX Acquired by Precision Wealth Strategies LLC - MarketBeat
Inspire Investing LLC Acquires Shares of 522,482 CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
CytomX Therapeutics (STU:6C1) EV-to-OCF : -7.46 (As of Dec. 26, 2025) - GuruFocus
CytomX Therapeutics (NASDAQ:CTMX) Trading Up 5.4%Here's Why - MarketBeat
CytomX Therapeutics: EpCAM Is Back, Now Prove It Holds (Rating Downgrade) (NASDAQ:CTMX) - Seeking Alpha
CTMX (CytomX Therapeutics) EV-to-OCF : -7.47 (As of Dec. 22, 2025) - GuruFocus
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress - Insider Monkey
Can CytomX Therapeutics Inc. stock sustain free cash flow growthJuly 2025 News Drivers & Weekly High Return Opportunities - ulpravda.ru
Market Outlook: Why CytomX Therapeutics Inc stock could outperform in 2025Buy Signal & Free High Accuracy Swing Entry Alerts - moha.gov.vn
Sell Signal: Will CytomX Therapeutics Inc stock recover faster than peersJuly 2025 Summary & High Return Trade Guides - moha.gov.vn
Is CytomX Therapeutics Inc. stock a top pick in earnings seasonPortfolio Update Report & Expert Verified Stock Movement Alerts - Улправда
How CytomX Therapeutics Inc. stock trades during market volatilityJuly 2025 Update & Fast Gain Swing Trade Alerts - Улправда
Is CytomX Therapeutics Inc. (6C1) stock undervalued by metricsJuly 2025 Sentiment & Community Trade Idea Sharing Platform - Улправда
Is CytomX Therapeutics Inc. stock gaining market share2025 Geopolitical Influence & Technical Pattern Recognition Alerts - Улправда
Is CytomX Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 PreEarnings & AI Driven Price Forecasts - DonanımHaber
CytomX Therapeutics' (NASDAQ:CTMX) earnings growth rate lags the 256% return delivered to shareholders - simplywall.st
Pullback Watch: What market sentiment indicators show for CytomX Therapeutics Inc. (6C1) stockMarket Performance Recap & Long-Term Safe Investment Plans - Улправда
Aug Opening: Is CytomX Therapeutics Inc. stock gaining market shareJuly 2025 PostEarnings & AI Enhanced Trading Alerts - Улправда
Will CytomX Therapeutics Inc. stock split attract more investorsBuy Signal & Expert-Curated Trade Recommendations - Улправда
CytomX Therapeutics (NASDAQ:CTMX) Trading Down 3.5%What's Next? - MarketBeat
Market Overview: Will CytomX Therapeutics Inc. stock split attract more investorsTake Profit & Fast Momentum Stock Entry Tips - Улправда
CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling - Seeking Alpha
CytomX Therapeutics2025 Funding Rounds & List of Investors - Tracxn
5,769,230 Shares in CytomX Therapeutics, Inc. $CTMX Acquired by Vivo Capital LLC - MarketBeat
Can CytomX Therapeutics Stock Recover If Markets Fall? - Trefis
What analysts say about CytomX Therapeutics Inc stockVolume Weighted Average Price & Explosive Profit Potential - earlytimes.in
With CytomX Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
What Analysts Think Is Changing the CytomX Therapeutics Story After Recent Cancer Developments - Yahoo Finance
CytomX Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of key data By Investing.com - Investing.com South Africa
CytomX Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of key data - Investing.com UK
Is CytomX Therapeutics Inc. stock a contrarian buyJuly 2025 PostEarnings & Technical Confirmation Alerts - Newser
Will CytomX Therapeutics Inc. stock beat EPS estimatesMarket Performance Report & Reliable Breakout Forecasts - Newser
Is CytomX Therapeutics Inc. (6C1) stock suitable for passive index funds2025 Earnings Surprises & Safe Entry Momentum Tips - Newser
Why CytomX Therapeutics Inc. (6C1) stock is listed among top recommendationsTrade Entry Report & High Accuracy Trade Alerts - Newser
Is CytomX Therapeutics Inc. (6C1) stock attractive post correctionProduct Launch & Real-Time Stock Movement Alerts - Newser
Published on: 2025-12-04 14:11:00 - Newser
Will CytomX Therapeutics Inc. (6C1) stock sustain dividend payoutsJuly 2025 Sector Moves & Verified Short-Term Plans - Newser
Would You Still Hold CytomX Therapeutics Stock If It Fell Another 30%? - Trefis
CytomX Therapeutics (NASDAQ:CTMX) Trading Down 6.5%What's Next? - MarketBeat
Is CytomX Therapeutics Inc. (6C1) stock ideal for retirement investorsJuly 2025 Patterns & Fast Gain Stock Trading Tips - Newser
What insider purchases suggest about CytomX Therapeutics Inc. (6C1) stockFed Meeting & Fast Gain Stock Trading Tips - Newser
Is CytomX Therapeutics Inc. (6C1) stock a buy on weaknessQuarterly Trade Summary & Fast Entry High Yield Tips - Newser
Will CytomX Therapeutics Inc. (6C1) stock outperform Dow JonesSell Signal & High Return Stock Watch Alerts - Newser
How CytomX Therapeutics Inc. (6C1) stock reacts to weak economy2025 Price Targets & Entry Point Confirmation Alerts - Newser
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):